WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H201684
CAS#: 159752-10-0 (mesylate)
Description: Ibutamoren, also known as MK-677, MK-0667, and L-163,191, is a non-peptidic, potent, long-acting, orally-active, and selective agonist of the ghrelin receptor and a growth hormone secretagogue, mimicking the growth hormone (GH)-stimulating action of the endogenous hormone ghrelin. It has been demonstrated to increase the release of, and produces sustained increases in plasma levels of several hormones including GH and insulin-like growth factor 1 (IGF-1), but without affecting cortisol levels.
Hodoodo Cat#: H201684
Name: Ibutamoren mesylate
CAS#: 159752-10-0 (mesylate)
Chemical Formula: C28H40N4O8S2
Exact Mass: 0.00
Molecular Weight: 624.770
Elemental Analysis: C, 53.83; H, 6.45; N, 8.97; O, 20.49; S, 10.26
Related CAS #: 159752-10-0 (mesylate) 159634-47-6 (free base)
Synonym: Ibutamoren; L 163191; L163191; L-163191; MK0677; MK-0677; MK0677; MK677; MK-677; MK 677.
IUPAC/Chemical Name: 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-(phenylmethoxy)propan-2-yl]propanamide mesylate.
InChi Key: DUGMCDWNXXFHDE-VZYDHVRKSA-N
InChi Code: InChI=1S/C27H36N4O5S.CH4O3S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27;1-5(2,3)4/h4-12,22H,13-19,28H2,1-3H3,(H,29,33);1H3,(H,2,3,4)/t22-;/m1./s1
SMILES Code: CC(C)(N)C(N[C@H](COCC1=CC=CC=C1)C(N2CCC3(CC2)CN(S(=O)(C)=O)C4=C3C=CC=C4)=O)=O.OS(=O)(C)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# CAS#159752-10-0 (Ibutamoren mesylate) CAS#159634-47-6 (Ibutamoren free base)
| Biological target: | Ibutamoren Mesylate (MK-677) is a potent, non-peptide Growth hormone secretagogue receptor (GHSR) agonist. |
| In vitro activity: | TBD |
| In vivo activity: | The quantitative analysis showed that the number of NeuN-positive cells and SYN immunoreactivity were significantly decreased in the neocortex of vehicle-treated 5XFAD mice compared with the vehicle-treated wild-type mice (Figure 3). In contrast, the number of NeuN-positive cells per area (Figure 3A) and optical density of SYN (Figure 3B) were significantly higher in the MK-0677-administered 5XFAD mice compared with the vehicle-injected 5XFAD mice. These results demonstrated that neuronal and synaptic loss in the brains of 5XFAD mice was ameliorated by treatment with MK-0677. Reference: Int J Mol Sci. 2018 Jun; 19(6): 1800. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032329/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 59.4 | 95.03 | |
| DMF | 25.0 | 40.01 | |
| Ethanol | 10.0 | 16.01 | |
| PBS (pH 7.2) | 10.0 | 16.01 | |
| Ethanol | 55.0 | 88.03 |
The following data is based on the product molecular weight 624.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Jeong YO, Shin SJ, Park JY, Ku BK, Song JS, Kim JJ, Jeon SG, Lee SM, Moon M. MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer's Disease. Int J Mol Sci. 2018 Jun 18;19(6):1800. doi: 10.3390/ijms19061800. PMID: 29912176; PMCID: PMC6032329. 2. Tian J, Wang T, Wang Q, Guo L, Du H. MK0677, a Ghrelin Mimetic, Improves Neurogenesis but Fails to Prevent Hippocampal Lesions in a Mouse Model of Alzheimer's Disease Pathology. J Alzheimers Dis. 2019;72(2):467-478. doi: 10.3233/JAD-190779. PMID: 31594237; PMCID: PMC7153492. |
| In vitro protocol: | TBD |
| In vivo protocol: | 1. Jeong YO, Shin SJ, Park JY, Ku BK, Song JS, Kim JJ, Jeon SG, Lee SM, Moon M. MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer's Disease. Int J Mol Sci. 2018 Jun 18;19(6):1800. doi: 10.3390/ijms19061800. PMID: 29912176; PMCID: PMC6032329. 2. Tian J, Wang T, Wang Q, Guo L, Du H. MK0677, a Ghrelin Mimetic, Improves Neurogenesis but Fails to Prevent Hippocampal Lesions in a Mouse Model of Alzheimer's Disease Pathology. J Alzheimers Dis. 2019;72(2):467-478. doi: 10.3233/JAD-190779. PMID: 31594237; PMCID: PMC7153492. |
1: Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011 Sep-Oct;53(2):183-9. doi: 10.1016/j.archger.2010.10.004. Epub 2010 Nov 9. PubMed PMID: 21067829.
2: Bach MA, Rockwood K, Zetterberg C, Thamsborg G, Hébert R, Devogelaer JP, Christiansen JS, Rizzoli R, Ochsner JL, Beisaw N, Gluck O, Yu L, Schwab T, Farrington J, Taylor AM, Ng J, Fuh V; MK 0677 Hip Fracture Study Group. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc. 2004 Apr;52(4):516-23. PubMed PMID: 15066065.
3: Prahalada S, Block G, Handt L, DeBurlet G, Cahill M, Hoe CM, van Zwieten MJ. Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration. Horm Metab Res. 1999 Feb-Mar;31(2-3):133-7. PubMed PMID: 10226793.
4: Schleim KD, Jacks T, Cunningham P, Feeney W, Frazier EG, Niebauer GW, Zhang D, Chen H, Smith RG, Hickey G. Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation. Endocrinology. 1999 Apr;140(4):1552-8. PubMed PMID: 10098487.
5: Bailey AR, Smith RG, Leng G. The nonpeptide growth hormone secretagogue, MK-0677, activates hypothalamic arcuate nucleus neurons in vivo. J Neuroendocrinol. 1998 Feb;10(2):111-8. PubMed PMID: 9535057.
6: Hickey GJ, Jacks TM, Schleim KD, Frazier E, Chen HY, Krupa D, Feeney W, Nargund RP, Patchett AA, Smith RG. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles. J Endocrinol. 1997 Feb;152(2):183-92. PubMed PMID: 9071975.
7: Jacks T, Smith R, Judith F, Schleim K, Frazier E, Chen H, Krupa D, Hora D Jr, Nargund R, Patchett A, Hickey G. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology. 1996 Dec;137(12):5284-9. PubMed PMID: 8940347.
8: Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5. PubMed PMID: 7624358; PubMed Central PMCID: PMC41459.
